| Ardry Lance Yarbrough, MD | |
|
1504 S Virginia Ave, Atoka, OK 74525-3246 | |
| (580) 889-4746 | |
| (580) 889-4735 |
| Full Name | Ardry Lance Yarbrough |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 1504 S Virginia Ave, Atoka, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386669745 | NPI | - | NPPES |
| 100130780A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 22046 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health Of Southeast Oklahoma | Hugo, OK | Home health agency |
| Mays Hospice Care, Inc | Antlers, OK | Hospice |
| Atoka County Medical Center | Atoka, OK | Hospital |
| Alliancehealth Durant | Durant, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carrus Care Physicians Group Inc | 3476898040 | 39 |
News Archive
A new article published in Regenerative Medicine reviews the latest advances in magnetic particle tracking in cell therapy, a potentially groundbreaking strategy in disease treatment and regenerative medicine.
Parkinson's disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson's.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.
Using a newly released method to analyze functional magnetic resonance imaging (fMRI), Northwestern University researchers have demonstrated that the interconnections between different parts of the brain are dynamic and not static.
› Verified 6 days ago
| Entity Name | Carrus Care Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336637123 PECOS PAC ID: 3476898040 Enrollment ID: O20190628001320 |
News Archive
A new article published in Regenerative Medicine reviews the latest advances in magnetic particle tracking in cell therapy, a potentially groundbreaking strategy in disease treatment and regenerative medicine.
Parkinson's disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson's.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.
Using a newly released method to analyze functional magnetic resonance imaging (fMRI), Northwestern University researchers have demonstrated that the interconnections between different parts of the brain are dynamic and not static.
› Verified 6 days ago
| Entity Name | Carrus Lakeside Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538921184 PECOS PAC ID: 1850789785 Enrollment ID: O20240208002977 |
News Archive
A new article published in Regenerative Medicine reviews the latest advances in magnetic particle tracking in cell therapy, a potentially groundbreaking strategy in disease treatment and regenerative medicine.
Parkinson's disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson's.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.
Using a newly released method to analyze functional magnetic resonance imaging (fMRI), Northwestern University researchers have demonstrated that the interconnections between different parts of the brain are dynamic and not static.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ardry Lance Yarbrough, MD 1504 S Virginia Ave, Atoka, OK 74525-3246 Ph: (580) 889-4746 | Ardry Lance Yarbrough, MD 1504 S Virginia Ave, Atoka, OK 74525-3246 Ph: (580) 889-4746 |
News Archive
A new article published in Regenerative Medicine reviews the latest advances in magnetic particle tracking in cell therapy, a potentially groundbreaking strategy in disease treatment and regenerative medicine.
Parkinson's disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson's.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.
Using a newly released method to analyze functional magnetic resonance imaging (fMRI), Northwestern University researchers have demonstrated that the interconnections between different parts of the brain are dynamic and not static.
› Verified 6 days ago
Dr. Joaquin Mauricio Forbes, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1201 W Liberty Rd, Atoka, OK 74525 Phone: 580-889-1981 Fax: 580-889-4009 | |
Dr. Bailey Camille Buck, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1585 W Liberty Rd, Atoka, OK 74525 Phone: 580-889-1981 | |
Noel W. Emerson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1510 S Virginia Ave, Atoka, OK 74525 Phone: 580-889-6621 Fax: 580-889-3602 |